144
Participants
Start Date
September 25, 2019
Primary Completion Date
November 9, 2021
Study Completion Date
November 9, 2021
Preventive strategy
In the experimental strategy, NIV is performed after inclusion in patients with moderate hypoxemia, defined by a PaO2/FiO2 ratio \< 300 mmHg. The minimally required duration of NIV was 4 hours per day for at least 2 calendar days. The daily duration of NIV can be increased at the discretion of the physician in patients with signs of delayed respiratory failure under HFNC-O2 and improving under NIV. Beyond the first 48 hours, NIV and HFNC-O2 can be stopped and the patient switched to COT if respiratory rate \< 25/min and SpO2 \> 92% under FiO2 \< 30% for at least 6 hours.
Standard of care
In the control group, patients receive oxygen from nasal cannula or high concentration oxygen mask according to the FiO2 needed to achieve SpO2 \> 92%. NIV is initiated only in patients having PaO2/FiO2 ratio \< 200 mmHg under COT. A trial of curative NIV is allowed at the discretion of the physician in patients who have signs of delayed respiratory failure and no other organ dysfunction. The non-improvement of respiratory conditions after 1 hour of NIV, the NIV-dependence (≥ 12 consecutive hours) or NIV-intolerance should be considered as criteria for endotracheal intubation.
AP-HM - Hôpital de la Timone, Marseille
CHU de Nîmes, Nîmes
CHU de Bordeaux, Bordeaux
Hôpital Robert Picqué, Villenave-d'Ornon
CHU de Saint Etienne, Saint-Priest-en-Jarez
CHU de Clermont-Ferrand, Clermont-Ferrand
CH de Pau, Pau
CHU de Strasbourg - Hôpital Civil, Strasbourg
CHU de Strasbourg -Hôpital de Hautepierre, Strasbourg
HCL - Hôpital Lyon Sud, Pierre-Bénite
CHU Amiens-Picardie, Amiens
CHU de Poitiers, Poitiers
APHP - Hôpital Beaujon, Clichy
CH d'Annecy, Annecy
University Hospital, Bordeaux
OTHER